Medical/Pharmaceuticals
SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan
TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ultrasound (HIFU)...
2023-02-02 14:00
2512
Global Times: Small and mid-sized cities in China go through infection peak, bearing new hope for future
BEIJING, Feb. 1, 2023 /PRNewswire/ -- As media sources around the world have paid so much attention to infection surges in various metropolises or first-and-second-tier cities inChina and governments at all levels have attached great importance to anti-epidemic work in rural areas, a review on ho...
2023-02-01 22:45
3194
Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved
WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other mo...
2023-02-01 22:08
2175
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
* Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high * Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout inChina expected in 2023 * Top-line data from tanfanercept's Phase 3 dry eye study e...
2023-02-01 20:00
2608
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution of a collaboration agreement with F. Hoffmann-La Roche L...
2023-01-31 21:50
4331
Global Times: 'So much better than we had anticipated': China's rural regions embrace Spring Festival as COVID peak ebbs away
BEIJING, Jan. 31, 2023 /PRNewswire/ -- The Spring Festival is rooted in agricultural civilization. Chinese people believe the most traditional atmosphere of Spring Festival is in rural regions. Since the prevention and control of the COVID-19 epidemic has entered a new stage, questions have been...
2023-01-31 21:41
3060
Guardant Health to integrate Lunit's AI-based scoring algorithm for PD-L1 into its portfolio to enhance cancer biomarker detection
* Powered by Lunit SCOPE PD-L1, the Guardant360 TissueNext PD-L1 test with Guardant Galaxy™ shows improved detection of the biomarker in NSCLC * Lunit's AI solution is the first application in Guardant Galaxy, a suite of AI and other technology tools that enhance Guardant Health's portfolio of...
2023-01-31 21:05
3162
Zhongchao Inc. Announces Introduction of Indian Anti-influenza Drugs to China
SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang...
2023-01-31 20:30
2644
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment inAustralia, the United States, and Italy * Presented compelling bioMUSE data at two prestigious industry conferences * Granted a 20-year patent for 100 new compounds targeting Parkinson's...
2023-01-31 20:25
5232
Singleron to present single cell sequencing solutions at the 36th Molecular Biology of Plants Conference
COLOGNE, Germany, Jan. 31, 2023 /PRNewswire/ -- Singleron Biotechnologies
2023-01-31 16:00
3080
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autolog...
2023-01-31 09:24
3114
Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China
BEIJING, Jan. 30, 2023 /PRNewswire/ -- Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in p...
2023-01-30 23:00
3098
Health in Tech to Attend Health Care Administration Association (HCAA) Executive Forum 2023 as Corporate Sponsor
HCAA's Executive Forum 2023 is scheduled for February 20-22, 2023, at the Bellagio inLas Vegas. Be sure to stop by booth NL #9 to meet Health in Tech leadership. STUART, Fla., Jan. 30, 2023 /PRNewswire/ -- Health in Tech ("HIT", or "the Company"), an industry-leading Insurtech company that deliv...
2023-01-30 22:00
2215
Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases
SHANGHAI, Jan. 29, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially ...
2023-01-30 10:00
2794
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...
2023-01-27 20:00
5118
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion. * FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit ofKRW 983.6 billion. * Strong growth momentum expected to continue with active expansions in capacity, geography, an...
2023-01-27 14:52
4628
Akeso Received First Tranche of US$300 Million Upfront Payment from Summit! Summit Is Accelerating Clinical Development of Ivonescimab
HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced the Hart-Scott-Rodino (HSR) Act filing has c...
2023-01-26 20:24
4590
SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
* First Generic of Abraxane in Korea, World 4th Commercial Scale-Up * Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea ,Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEOJang Doo-hyun) signed a domestic manufacturing technology transf...
2023-01-26 14:31
3112
ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative medicine industry has shown tremendous potential in clinical practices in recent years worldwide,China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or "...
2023-01-26 12:11
2759
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...
2023-01-26 10:34
2647
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
12552
